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Abstract
Recessively inherited variants in AARS2 (NM_020745.2) encoding mitochondrial alanyl-tRNA synthetase (mt-AlaRS) were
first described in patients presenting with fatal infantile cardiomyopathy and multiple oxidative phosphorylation defects.
To date, all described patients with AARS2-related fatal infantile cardiomyopathy are united by either a homozygous or
compound heterozygous c.1774C>T (p.Arg592Trp) missense founder mutation that is absent in patients with other
AARS2-related phenotypes. We describe the clinical, biochemical and molecular investigations of two unrelated boys
presenting with fatal infantile cardiomyopathy, lactic acidosis and respiratory failure. Oxidative histochemistry showed
cytochrome c oxidase-deficient fibres in skeletal and cardiac muscle. Biochemical studies showed markedly decreased
activities of mitochondrial respiratory chain complexes I and IV with a mild decrease of complex III activity in skeletal and
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cardiac muscle. Using next-generation sequencing, we identified a c.1738C>T (p.Arg580Trp) AARS2 variant shared by both
patients that was in trans with a loss-of-function heterozygous AARS2 variant; a c.1008dupT (p.Asp337*) nonsense variant or
an intragenic deletion encompassing AARS2 exons 5–7. Interestingly, our patients did not harbour the p.Arg592Trp AARS2
founder mutation. In silico modelling of the p.Arg580Trp substitution suggested a deleterious impact on protein stability and
folding. We confirmed markedly decreased mt-AlaRS protein levels in patient fibroblasts, skeletal and cardiac muscle,
although mitochondrial protein synthesis defects were confined to skeletal and cardiac muscle. In vitro data showed that the
p.Arg580Trp variant had a minimal effect on activation, aminoacylation or misaminoacylation activities relative to wild-type
mt-AlaRS, demonstrating that instability of mt-AlaRS is the biological mechanism underlying the fatal cardiomyopathy
phenotype in our patients.
Introduction
Mitochondrial respiratory chain disorders are among the most
common early onsetmetabolic disorderswith an estimatedmin-
imum prevalence of 1 in 5000 live births (1). Isolated or multiple
deficiencies of the fivemultimeric complexes (I–V) that comprise
the oxidative phosphorylation (OXPHOS) system are associated
with broad clinical, biochemical and genetic heterogeneity. Dis-
orders of mitochondrial mRNA translation or protein synthesis
are especially important causes of multiple mitochondrial respi-
ratory chain deficiency, which are linked to both mitochondrial
DNA (mtDNA) and nuclear gene defects (2).
Following post-transcriptional modification, a critical step
of mitochondrial protein synthesis is the aminoacylation or
‘charging’ of transfer RNAs (tRNAs) (3). This step involves
the recognition and conjugation of amino acids with their
corresponding cognate mitochondrial transfer RNA (mt-tRNA),
as dictated by the codon sequence. Attachment is catalysed
by mitochondrial aminoacyl-tRNA synthetases (mt-aaRS) that
are encoded by nuclear genes and imported into mitochondria.
There are 17 mt-aaRS and two dual cytosolic-mitochondrial
synthetases (GlyRS, LysRS), while mt-GluRS is required to
efficiently misaminoacylate tRNAGln to form Glu-tRNAGln in
mitochondria (4,5).
All mt-aaRS and dual-localized synthetases are associated
with autosomal recessive human disorders manifesting in
clinically and biochemically heterogeneous phenotypes (6–8).
Despite ubiquitous expression, autosomal recessive mt-aaRS
disorders are associated with intriguing tissue- and cell-specific
phenotypes that typically involve the central nervous system
(9–18). High-throughput, next-generation sequencing tech-
nologies have greatly expanded the phenotypic continuum
of mt-aaRS disorders to encompass patients presenting with
additional clinical features or with the absence previously
considered salient features.
Recessively inherited variants in AARS2 (NM_020745.2),
encoding mitochondrial alanyl-tRNA synthetase (mt-AlaRS),
were first described in patients presenting with fatal infantile
cardiomyopathy and multiple OXPHOS defects (19), with
additional patients subsequently identified (20–24). However,
the spectrum of AARS2-related disease has expanded to include
childhood to adulthood-onset leukoencephalopathy with
premature ovarian failure (POF) in females (9,25–28), retinopathy
and optic atrophy (29) and fatal non-immunehydrops fetalis (30);
all with conspicuous absence of cardiac involvement. Currently,
AARS2-related fatal infantile cardiomyopathy is associated
with a recurrent pathogenic c.1774C>T (p.Arg592Trp) founder
mutation that is either homozygous or compound heterozygous
in all described patients. This founder mutation has not been
reported in patients presenting with other AARS2-related phe-
notypes. Consequently, the spectrum of AARS2-related disease
phenotypes has been attributed to the location of pathogenic
variants in the protein and the effect on protein function (22). It
has been previously hypothesized that the p.Arg592Trp AARS2
founder mutation, which occurs in a conserved editing domain,
causes a severe decrease in aminoacylation due to impaired
tRNA binding and positioning of the 3′-end within the active site
(22). On the other hand, otherAARS2-related disease phenotypes
were predicted to result from only a partial reduction in
aminoacylation activities (22). This mt-AlaRS editing domain
is required for the deacylation of mischarged tRNAs, since the
aminoacylation domain is unable to discriminate alanine with
serine and glycine (31,32). This proofreading activity is essential
to clear mischarged Ser-tRNAAla and avoid misincorporation
of serine at alanine codons, since a slight decrease results in
embryonic lethality in mice (33). Of all mt-aaRS, only mt-AlaRS
and mt-ThrRS have demonstrable editing activities to prevent
the formation of mischarged mt-tRNAs (31,32,34).
In this study, we describe two unrelated patients presenting
with fatal infantile cardiomyopathy, lactic acidosis and res-
piratory failure, with severe multiple OXPHOS deficiency and
who both harboured an unreported AARS2 variant (c.1738C>T,
p.Arg580Trp) in trans with a loss-of-function AARS2 variant,
but not the recurrent p.Arg592Trp founder mutation. We
validate pathogenicity of this shared novel mt-AlaRS editing
domain variant through post-mortemmolecular studies, in silico
modelling and in vitro assays. This data supports the genotype–
phenotype correlation between AARS2 variants in the ß-barrel
domain with fatal cardiomyopathy and that instability of mt-
AlaRS due to the novel p.Arg592Trp and loss-of-function alleles
is the underlying biological mechanism in our patients.
Results
Case reports
Patient 1. Patient 1 was a male infant born at term by normal
vaginal delivery to non-consanguineous parents with a birth
weight of 3.11 kg. He developed respiratory distress and poor
respiratory drive soon after birth, requiring ventilation. He had
generalized hypotonia and evidence of diaphragmatic paraly-
sis with paradoxical abdominal wall movements. There was
persistent lactic acidemia (9–30 mmol/L; normal <2.5 mmol/L).
Urine organic and amino acids were unremarkable apart from
increased lactate excretion. There were no seizures and he tol-
erated nasogastric feeding. Initial echocardiography showed no
evidence of cardiomyopathy, but he developedmild biventricular
hypertrophy by 5 weeks of age. This was associated with periods
of cardiac electrical inactivity, lasting 6–7 s and later up to 30 s.
He was weaned off ventilatory support at 6 weeks and died
1 week later. Whole mitochondrial genome sequencing failed to
detect a pathogenic variant, while quantitative real-time poly-
merase chain reaction (PCR) assay of skeletal muscle mtDNA
copy number was normal (data not shown). A previous daughter
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was born at term and died within 24 h with lactic acidemia and
coagulopathy. Post-mortem analysis of this female sibling is said
to have shown pulmonary hypoplasia. There is one healthy son
and the child’s mother had two previous miscarriages.
Patient 2. Patient 2, a male infant, was a dizyotic twin born at
33 weeks gestation by caesarean section to non-consanguineous
parents with a birthweight of 1.595 kg.He presented at 2months
of age with respiratory failure secondary to respiratory syncytial
virus bronchiolitis. An echocardiogram revealed severe concen-
tric left ventricular hypertrophy and dilation and severe systolic
dysfunction. (Fig. 1D) Brain magnetic resonance imaging noted
a thin corpus callosum, but neurological examination was nor-
mal. He required ongoing mechanical ventilation for respiratory
failure. He received two courses of venoarterial extracorporeal
membrane oxygenation for circulatory support and was transi-
tioned to a Berlin left ventricular assist device at 5 months of
age. Aside from persistent lactic acidemia (2–16 mmol/L; normal
<2.5 mmol/L), extensive biochemical evaluation was unremark-
able. He developedmulti-organ failure and suffered a left middle
cerebral artery stroke with residual neurologic dysfunction and
muscular weakness at 6 months of age. Palliative care was
initiated and he died at 7months of age. Post-mortem evaluation
demonstrated a markedly enlarged globular heart with biven-
tricular hypertrophy and severemyocyte vacuolization.Negative
genetic evaluations included karyotype, single nucleotide poly-
morphism (SNP) microarray, urinemitochondrial genome analy-
sis and a targeted 89-gene cardiomyopathy panel. The patients’
male twin was diagnosed with Trisomy 18 prenatally and died
at birth with unknown cardiac status. An older female sibling
was born at term and died at birth with significant cardiomegaly
noted post-mortem. Parental echocardiograms were normal.
Diagnostic histochemical and biochemical analyses of
skeletal and cardiac muscle reveal severe multiple
mitochondrial OXPHOS defects
Histopathologic analysis of skeletal muscle from Patient 1
showed vacuolated fibreswith increased lipid.Oxidative enzyme
histochemistry showed absent c oxidase (COX) activity in 50%
of fibres (Fig. 1A), although an assessment of sequential COX–
succinate dehydrogenase (SDH) histochemistry was not made.
In Patient 2, oxidative enzyme histochemistry of post-mortem
skeletal and cardiac muscle revealed global COX-deficiency
(Fig. 1A). Post-mortem histopathologic analysis of the heart
noted marked biventricular myocyte vaculosation, myocyte
hypertrophy and mild subendocardial fibrosis (Fig. 1Bi), com-
pared to an age-matched control (Fig. 1Bii). Electron microscopy
of cardiac muscle showed no ultrastructural evidence for a
mitochondrial disorder but demonstrated vacuolar myopathic
changes with large membrane bound vesicles containing
glycogen.
Biochemical analysis of mitochondrial respiratory chain
complex activities (Fig. 1C) revealed markedly decreased
complex I and complex IV activities with low complex III activity
in Patient 1 and Patient 2 skeletal muscle relative to controls.
Similarly, severe complex I and complex IV activities with low
complex III activity were also noted in the cardiac muscle from
Patient 2, relative to age-matched controls.
Identification of recessively inherited AARS2 variants
In Patient 1, analysis of whole exome sequencing (WES)
called variants in nuclear genes encoding mitochondrial-
localized proteins revealed two heterozygous variants in
AARS2 (NM_020745.2); c.1008dupT, (p.Asp337*) and c.1738C>T
(p.Arg580Trp), which were confirmed by Sanger sequencing
(Fig. 2A). Unfortunately, familial segregation studies were not
possible. In Patient 2, whole genome sequencing (WGS) revealed
the identical heterozygous c.1738C>T (p.Arg580Trp) AARS2
missense variant that was paternally inherited and confirmed
by Sanger sequencing (Fig. 2A). Visual inspection of read
alignments and using IGV (35) also identified a maternally
inherited, intragenic 4.1 kb deletion on the short arm of
chromosome 6p21.1 encompassing exons 5–7 of AARS2, which
was confirmed to segregate with the disease by long-range
PCR (Fig. 2B).
None of the identified variants were previously reported as
pathogenic and both patients did not harbour the p.Arg592Trp
AARS2 foundermutation. InGnomAD, the c.1008dupT(p.Asp337*)
variant was present in 3/245814 (minor allele frequency
(MAF) = 1.22 × 10−5) alleles and the c.1738C>T (p.Arg580Trp)
variant was present in 9/246174 (MAF = 3.656 × 10−5) alleles, all
in heterozygous state. The p.Arg580Trp variant was predicted
to be damaging by the in silico tools PolyPhen-2 (HumDiv Score
0.996) (36) and SIFT (Score 0.02) (37) but was predicted to be
benign by Align GVGD (Class 0, GV: 127.27, GD: 46.61) (38).
According to the American College ofMedical Genetics guide-
lines for characterization of sequence variants, the novel AARS2
p.Arg580Trp variant did not meet the criteria for classification
as ‘likely pathogenic’ variant. Therefore, we decided to pursue
functional analyses to confirm pathogenicity of the identified
AARS2 variants.
Structural modelling of the p.Arg580Trp AARS2 variant
We first examined the sequence conservation of the Arg580
residue and modelled the p.Arg580Trp variant using the avail-
able structural model for mt-AlaRS (22). The Arg580 residue
is conserved in this position among mt-AlaRS in mammals
and birds but not in the lizard Anolis carolinensis, fish Danio
rerio, fly Drosophila melanogaster, worm Caenorhabditis elegans or
yeast Saccharomyces cerevisiae (Fig. 3A).However, a bulky aromatic
residue in the corresponding position is not found in any of
the analysed mt-AlaRS sequences. Arg580 is one of the solvent
exposed residues on the surface of the β-barrel subdomain
(530–621 aa) of the mt-AlaRS editing domain and is involved in
complex electrostatic, hydrophobic and hydrogen interactions
with neighbouring residues. This suggests a structural role for
Arg580 and an impact on protein folding and stability. Substi-
tution of an arginine to a hydrophobic and bulky tryptophan is
predicted to affect folding of the β-barrel subdomain and as a
result compromise the stability of the entire protein (Fig. 3B).
mt-AlaRS protein levels are diminished in patient
fibroblasts without defective mitochondrial protein
synthesis
We assessed steady-state mt-AlaRS and OXPHOS complex sub-
unit protein levels in fibroblast lysates from Patient 1 and two
patients harbouring the p.Arg592TrpAARS2 foundermutation on
at least one allele (Fig. 4A). Cultured fibroblasts were not avail-
able from Patient 2. Quantification of steady-state levels of mt-
AlaRS showed a statistically significant decrease in all patients
(Fig. 4B). However, there was no change in OXPHOS complex
subunit levels (Fig. 4A). Levels of mt-tRNAAla and the presence
of uncharged and charged species were also assessed in patient
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Figure 1. Histochemical and biochemical studies of AARS2 patient skeletal and cardiac muscle. (A) Diagnostic skeletal and cardiac muscle were subjected to COX, SDH
and sequential COX-SDH histochemical reactions. Skeletal muscle from Patient 1 was not subjected to sequential COX-SDH histochemistry. (B) Photomicrograph of
(i) Patient 2 cardiac muscle sampled at autopsy and (ii) healthy heart of a child of similar age. (C) Measurement of mitochondrial OXPHOS activities (CI-CV) normalized
to CS in skeletal (Patient 1 and 2) and cardiacmuscle (Patient 2), as a percentage of residual controls. Controls are denoted in blue, Patient 1 in red and Patient 2 in orange.
Decreased OXPHOS activities are denoted by asterisks (‘*’). (D) Echocardiographic images in the parasternal short axis view of Patient 2’s heart (i and ii; annotated in
panel ii) and the normal heart of a child approximately the same age (iii). The patient’s heart demonstrates severe concentric hypertrophy of the left ventricle (LV)
involving both the interventricular septum (IVS) and the posterior wall. Also identified is the right ventricle (RV).
fibroblasts. Northern blot analysis of total RNA from fibroblasts
of Patient 1 and an unrelated patient who was homozygous for
the recurrent p.Arg592Trp founder mutation showed no change
in the abundance of uncharged mt-tRNAAla (Fig. 4C). Analysis of
aminoacylated mt-tRNAAla showed the presence of charged Ala-
tRNAAla species with no uncharged tRNAAla in both patient and
control fibroblasts (Fig. 4D).
Patient skeletal and cardiac muscle have decreased
mt-AlaRS protein levels and mitochondrial protein
synthesis defects
Next, we examined steady-state mt-AlaRS and OXPHOS subunit
protein levels in skeletal and cardiac muscle homogenates from
Patient 2 (Fig. 5A). No skeletal or cardiac muscle was available
from Patient 1. Quantification of steady-state mt-AlaRS protein
levels showed a statistically significant decrease in both skeletal
and cardiac muscle homogenate from Patient 2; mt-AlaRS levels
were undetectable in cardiac homogenate (Fig. 5B). There was
marked loss of MT-COI (complex IV) and NDUFB8 (complex I)
subunits with a mild reduction of UQCRC2 (complex III). This
was consistent with the decreased biochemical activities for
complexes I, III and IV in skeletal and cardiac muscle (Fig. 1C).
We also quantified AARS2mRNA levels in cardiac muscle, which
confirmed an 50% decrease in AARS2 mRNA relative to controls
(data not shown).We then assessed mt-tRNAAla levels in cardiac
muscle from Patient 2 as well as an unrelated patient who was
homozygous for the p.Arg592Trp founder mutation. Northern
blot analysis showed decreased levels of uncharged mt-tRNAAla
in both patients (Fig. 5C). Unfortunately, the presence of charged
and uncharged mt-tRNAAla could not be assessed.
The p.Arg580Trp AARS2 variant likely has a minimal
effect on mitochondrial protein synthesis
We assessed the aminoacylation and editing activities of mt-
AlaRS with the p.Arg580Trp variant in vitro. ATP-PPi exchange
reaction assay showed that the p.Arg580Trp variant exhibited
the same amino acid activation activity compared to wild-type
mt-AlaRS, suggesting that there is no direct impact on the syn-
thetic active site (Fig. 6A). Next, an aminoacylation assay showed
that the p.Arg580Trp variant had comparable tRNAAla charg-
ing activity compared to wild-type human mt-AlaRS, suggest-
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Figure 2. Genetic analysis of identified AARS2 variants. (A) Family pedigrees showing Sanger sequencing confirmation of the c.1008dupT (p.Asp337*) and c.1738C>T
(p.Arg580Trp) AARS2 variants for Patient 1 and segregation of the c.1738C>T (p.Arg580Trp) variant for Patient 2. (B) Long-range PCR confirmation of a maternally
inherited, heterozygous intragenic 4.1 kb deletion on the short arm of chromosome 6p21.1 encompassing exons 5–7 of AARS2. A non-specific product at 2 kb does not
affect segregation analysis. The wild-type allele (5 kb) and the deleted allele (1 kb) are denoted by a solid red arrow.
ing that the speed of mitochondrial protein synthesis was not
affected (Fig. 6B).
To more accurately determine any defect in translational
quality control, [32P]tRNAAla was used in a misaminoacylation
assay. The free [32P]tRNAAla and the mischarged Ser-[32P]tRNAAla
were hydrolysed by nuclease S1 and the produced [32P]AMP
and Ser-[32P]AMP could be directly observed (Fig. 6C and D).
The p.Arg580Trp variant produced only negligibly (if any) more
Ser-tRNAAla when compared to wild-type human mt-AlaRS,
suggesting fidelity of protein synthesis was not significantly
impacted.
Finally, we overexpressed wild-type human mt-AlaRS and
the p.Arg580Trp mutant in HEK293T cells, demonstrating that
steady-state levels of the mt-AlaRS p.Arg580Trp mutant were
decreased relative to wild-type (Fig. 6E), which was consistent
with in silico modelling and decreased levels in patient tissues.
Discussion
Autosomal recessive AARS2 variants were first described in
patients with fatal infantile cardiomyopathy (19). Recently, the
clinical spectrum has expanded to include childhood and adult-
onset leukodystrophy (with POF in females) (9), retinopathy
and optic atrophy (29) and fatal non-immune hydrops fetalis
(30). However, cardiomyopathy is conspicuously absent in
more recently described phenotypes. Currently, there are 14
reported patients presenting with AARS2-related fatal infantile
cardiomyopathy (19,20,22–24) and one patient who died in utero
with myopathy, hypotonia and multiple fractures (21). These
reported patients all harbour at least one copy of the recurrent
p.Arg592Trp missense founder mutation.
In contrast, we report two unrelated patients presenting with
fatal infantile cardiomyopathy, lactic acidosis and respiratory
failure,with severemultiple OXPHOSdefects andwhoharboured
biallelic AARS2 variants but not the recurrent founder allele.
Instead, our patients both harboured a novel p.Arg580Trp mis-
sense variant that was compound heterozygous with a second,
loss-of-function AARS2 variant. Nonetheless, the clinical pre-
sentation of our patients was severe and broadly comparable
to the previously reported patients harbouring the p.Arg592Trp
founder mutation on at least one allele. For all patients, the
clinical course was fatal before 1 year of life with onset of cardiac
features either before or shortly after birth.
Mt-AlaRS is one of two reported mitochondrial synthetases
that have editing activities to prevent the formation of
mischarged mt-tRNAs (31,32,34). The conserved editing domain
of mt-AlaRS is essential since the aminoacylation domain
cannot discriminate alanine with serine and glycine, thus
avoiding the misincorporation of serine at alanine codons and
clearing mischarged Ser-tRNAAla (31,32). Both p.Arg580Trp and
p.Arg592Trp variants are located in the β-barrel subdomain
of the mt-AlaRS editing domain and involve an arginine to
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Figure 3. In silico modelling of the human mt-AlaRS Arg580 residue and p.Arg580Trp variant. (A) Multiple sequence alignment of the mt-AlaRS Arg580 residue across
species. (B) In silico modelling of the p.Arg580Trp variant on mt-AlaRS protein stability and intramolecular bonds. Editing site is highlighted with transparent green
sphere. It contains zinc-binding residues His632, His636, His753 and Cys749.
tryptophan substitution, while a β-barrel subdomain variant
(c.1616A>G, p.Tyr539Cys) has also been reported in trans with
the p.Arg592Trp founder mutation (24). However, the mutated
residues are not located in the editing core of mt-AlaRS. Previous
in silico modelling showed that the mt-AlaRS Arg592 residue is
surface exposed and forms one salt bridge with Glu567, which
is invariant in this position among cytosolic, mitochondrial and
bacterial homologues of the enzyme. The p.Arg592Trp founder
mutation was predicted to have a deleterious effect on tRNA
binding and a severe reduction in aminoacylation activity of mt-
AlaRS but with no effect on editing activity or protein stability
(22). Similarly, Arg580 is also solvent exposed but in contrast to
Arg592, it forms a number of different non-covalent bonds with
neighbouring residues that suggests importance of arginine in
this position for protein stability (Fig. 3). Hence, substitution of
the Arg580 residue with tryptophan is predicted to compromise
mt-AlaRS protein folding and stability.
Indeed, quantification of mt-AlaRS protein levels confirmed
a statistically significant decrease in fibroblasts, skeletal and
cardiac muscle from both patients harbouring the p.Arg580Trp
variant and in fibroblasts from two patients harbouring at least
one copy of the p.Arg592Trp founder allele (Fig. 4A and B, Fig. 5A
and B). Furthermore, mt-AlaRS protein levels appeared to be
decreased more in fibroblasts from Patient 1, who harboured
the p.Arg580Trp allele, compared to two patients with at least
one copy of the p.Arg592Trp founder mutation. Hence, this sup-
ports our in silicomodelling of the p.Arg580Trp missense change.
Decreased mt-AlaRS protein levels were accompanied by severe
multiple OXPHOS defects in patient skeletal and cardiac muscle
(Fig. 5A) but were absent in patient fibroblasts (Fig. 4A). This sug-
gests that skeletal and cardiac muscle are more susceptible to
mitochondrial protein synthesis defects,whilemt-AlaRS activity
is essential in cardiac cells during early development. Our in vitro
studies of mutant p.Arg580Trp mt-AlaRS also showed decreased
protein stability when overexpressed in HEK293T cells (Fig. 6E).
Decreased mt-tRNAAla levels were also observed in patient car-
diac muscle (Fig. 5C), confirming a deleterious effect on mito-
chondrial protein synthesis. However, our in vitro data clearly
showed that the p.Arg580Trp variant had little effect on amino
acid activation and aminoacylation activities (Fig. 6), which was
expected since it is not located near the aminoacylation active
site. These data also showed that the p.Arg580Trp variant did
not accumulate moremischarged tRNAAla in misaminoacylation
when compared towild-type humanmt-AlaRS, since the residue
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Figure 4. Western blot, northern blot and aminoacylation analysis in AARS2 patient fibroblast lysates. (A) Steady-state mt-AlaRS and OXPHOS subunit protein levels in
Patient 1 (P1) and two control fibroblast lysates. Also shown are two reported AARS2 patients in the literature who were homozygous or compound heterozygous for the
p.Arg592Trp founder mutation; Patient x (homozygous p.Arg592Trp) corresponds to Patient 11, and Patient y (p.Arg592Trp and c.2882C>T (p.Ala961Val)) corresponds to
Patient 7 in (24). Antibodies againstmt-AlaRS,NDUFB8 (CI), SDHA (CII), UQCRC2 (CIII),MT-COI (CIV) and ATP5B (CV) were used,with β-actin as a loading control. (B) Graph
of relative mt-AlaRS protein levels (n = 3) in controls, Patient 1 (P1), Patient x (x) and Patient y (y) fibroblasts. All data were normalized to SDHA and represented as
mean ± standard error of the mean. Significant difference between controls and patient fibroblasts is indicated by asterisks above the columns (*, P-value < 0.05;
**, P-value < 0.01 by two-tailed paired students t-test). (C) Northern blot analysis of mt-tRNAAla levels in patient fibroblasts. (D) Aminoacylation assay showing
aminoacylated (‘charged’) and deacylated (‘uncharged’) mt-tRNAAla in patient fibroblasts.Mitochondrial tRNAArg was used as a loading control. Lower bands in the dAc
lanes denote fully deacylated control tRNA species. Patient z was homozygous for the p.Arg592Trp foundermutation and has been previously reported, corresponding to
Patient 1 in (19).
is distant from the editing active site (∼40 Å). Moreover, it is
also not in the potential tRNA entrance pathway into the editing
active site during tRNA 3’-end translation. Taken together, our
data suggest that the p.Arg580Trp variant impacts on stability
of mt-AlaRS protein but not aminoacylation or editing activities
and that the β-barrel subdomain has a critical role in protein
folding and stability. The combination of the p.Arg580Trp vari-
ant in trans with a second, heterozygous loss-of-function allele
as detected in our patients, suggests that marked loss of mt-
AlaRS is sufficient to cause a severe defect of mitochondrial pro-
tein synthesis that manifests as fatal infantile cardiomyopathy.
Although skeletal and cardiac muscle appear more susceptible
to mitochondrial protein synthesis defects than other cell types
such as fibroblasts, data suggest that specific loss of mt-AlaRS
during early development has a highly detrimental effect on
cardiac cells. By contrast, loss of other mt-aaRS does not affect
cardiac function during early life. For example, a loss of mt-
GluRS protein due to recessively inherited EARS2 variants leads
to a severe, lethal neonatal leukoencephalopathy with thalamus
and brainstem involvement and high lactate (39), but with-
out cardiac involvement. Our findings continue to support the
hypothesis that there is an enhanced requirement formitochon-
drial protein synthesis in the heart in early life and that a 50%
reduction of aminoacylation activity is sufficient to maintain
mitochondrial translation (22). On the other hand, recessively
inherited variants causing other AARS2-related phenotypes are
predicted to cause only a partial loss of mt-AlaRS protein level or
aminoacylation activity, manifesting in childhood or adulthood
phenotypes but not in the heart (22). However, steady-state
mt-AlaRS protein levels have not yet been assessed in tissue
from patients with other AARS2-related disorders. Furthermore,
additional in vitro studies of the p.Arg592Trp founder mutation
are necessary to confirm any impact on amino acid activation,
aminoacylation and misaminoacylation activities. This would
determine whether p.Arg580Trp and p.Arg592Trp have a shared
biological mechanism or if disturbed tRNA binding with a severe
loss of aminoacylation activities or marked instability of mt-
AlaRS are two mechanisms that manifest clinically with fatal
cardiomyopathy, concurring with in silico models.
Overall, our data strengthen the importance of mt-AlaRS in
cardiac muscle during early embryonic development and the
relationship between β-barrel subdomain variants (p.Arg580Trp
and p.Arg592Trp) and the manifesting AARS2-related mitochon-
drial disease phenotypes.
Materials and Methods
Ethical compliance and informed consent
Informed consent for diagnostic and research-based studies was
obtained for all subjects in accordance with the Declaration of
Helsinki protocols and approved by local institutional review
boards.
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Figure 5. Western blot and northern blot analysis in AARS2 patient skeletal and cardiac muscle homogenates. (A) Steady-state mt-AlaRS and OXPHOS subunit protein
levels in Patient 2 skeletal and cardiac muscle homogenates. Antibodies against mt-AlaRS, NDUFB8 (CI), SDHA (CII), UQCRC2 (CIII), MT-COI (CIV) and ATP5B (CV) were
used, with SDHA as a loading control. (B) Graphs of relative mt-AlaRS protein levels in control and Patient 2 (P2) skeletal (n = 3) and cardiac muscle (n = 2) homogenate.
All data were normalized to SDHA (skeletal muscle) or VDAC (cardiac muscle) and represented as mean ± standard error of the mean. Significant difference between
controls and patient homogenates is indicated by asterisks above the columns (*, P-value < 0.05; **, P-value < 0.01 by two-tailed paired students t-test). (C) Northern blot
analysis of mt-tRNAAla levels in Patient 2 and Patient z who was homozygous for the p.Arg592Trp founder mutation, corresponding to Patient 1 in (19). Mitochondrial
tRNASer(AGY) was used as a loading control.
Histopathology, biochemical and molecular studies
Diagnostic skeletal muscle biopsies from both patients, endo-
myocardial biopsy and post-mortem cardiac muscle from
Patient 2 were processed and mounted on glass slides according
to standard procedures. Skeletal muscle biopsies (Patient 1
and 2) and post-mortem cardiac muscle (Patient 2) were
subjected to cytochrome COX, SDH and sequential COX-SDH
histochemical reactions (40). Mitochondrial OXPHOS activities
(complexes I–IV) relative to citrate synthase (CS) were measured
in skeletal (Patient 1 and 2) and cardiac muscle (Patient 2)
homogenates as previously described (41).Whole mitochondrial
genome sequencing of both patients was performed to exclude
pathogenic variants.Quantitative real-time PCR assay of skeletal
(Patient 1 and 2) and cardiac muscle DNA (Patient 2) was
performed to assessmtDNA copy number, according to standard
protocols.
Next-generation sequencing and genetic investigations
WES, filtering and candidate variant analysis was performed for
Patient 1 as described previously (39). In Patient 2, bidirectional
sequence from WGS was prepared using the Kapa Hyper
library prep omitting PCR, sequenced using the Illumina
HiSeq 2500 system utilizing paired end 2 × 125 base pair
reads with v4 Chemistry, aligned to reference gene sequences
based on human genome build GRCh37/UCSC hg19 and
variants were analysed using custom-developed software;
RUNES and VIKING (42,43). WES was performed on unaffected
parents of Patient 2. Patient 2 was sequenced to a depth
of 111.52 Gb for a mean coverage of ∼37x. Variants were
filtered with a MAF less than 1% and then prioritized by the
American College of Medical Genetics categorization. Align
GVGD (http://agvgd.hci.utah.edu/agvgd_input.php) (38), SIFT
(http://sift.jcvi.org/) (37) and PolyPhen-2 (http://genetics.bwh.
harvard.edu/pph2/) (36) were used to assess pathogenicity
of missense variants. Identified candidate variants were
confirmed by Sanger sequencing. Long-range PCR of the
AARS2 (NM_020745.2) gene was performed using forward
(5′-GTGGGGTCAGCCCTGTTCCT-3′) and reverse (5′-CAGGAAGGC
TGCCTCGTCCT-3′) primers.
Structural modelling
Structure prediction for human mt-AlaRS with bound tRNAAla
and alanyl-adenylate in the aminoacylation site was done as
earlier described (22). Briefly, a multiple sequence alignment of
different cytoplasmic, mitochondrial and bacterial homologues
of human mt-AlaRS was done using Promals3D server. The
resulting alignment was submitted to SWISS-MODEL server. As
a template for human mt-AlaRS structure modelling, the full-
length AlaRS from Archaeoglobus fulgiduswas used (PDB id 3WQY
chain A) (44). Docking of the tRNA and alanyl-adenylate into the
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Figure 6. In vitro studies of the human mt-AlaRS p.Arg580Trp mutant. (A)
ATP-PPi exchange determination of human mt-AlaRS (•) and the p.Arg580Trp
mutant (). A reaction at the absence of Ala was included for a control ().
(B) Aminoacylation activity of human mt-AlaRS (•) and the p.Arg580Trp mutant
(). (C) A representative TLC showing the mischarging of mt-tRNAAla by human
mt-AlaRS and the p.Arg580Trp mutant. Nuclease S1-generated Ser-[32P]AMP
(reflecting Ser-[32P]tRNAAla) and [32P]AMP (reflecting free [32P]tRNAAla) were
separated by TLC. (D) Graph of the mischarging activity of human mt-AlaRS
(•) and the p.Arg580Trp mutant (). In all graphs, the data represent the mean
valueswith error bars indicating standard deviation (SD). (E) Steady-state protein
level of overexpressed humanmt-AlaRS and the p.Arg580Trpmutant in HEK293T
cells.Genes encoding C-terminal FLAG-tagged humanmt-AlaRS and p.Arg580Trp
mutant were overexpressed in HEK293T cells and the proteins were detected by
FLAG antibodies. GAPDH was detected as a loading control.
model and structure analysis was done using Discovery Studio
v4.5 (BioVia) software.
Cell culture
Patient and control cultured skin fibroblasts were grown in
minimum essential medium (MEM) (Gibco) or Dulbecco’s
Modified Eagle Medium supplemented with 10% foetal bovine
serum (Gibco), 1× MEM vitamins (Sigma), 1× non-essential
amino acids (Sigma), 50 U/ml penicillin, 50 μg/ml streptomycin
(Sigma), 100 mm sodium pyruvate solution (Sigma), 0.05 mg/ml
uridine aqueous solution and 2 mm L-glutamine (Sigma).
Western blot analysis
Fibroblast lysates (50 μg), skeletal (25–50 μg) and cardiac muscle
(15–50 μg) homogenates were separated by 12% SDS-PAGE
and electrophoretically transferred to polyvinylidene difluoride
(PVDF) membranes (Bio-Rad). Primary antibodies used were
specific to mt-AlaRS (ab197367, Abcam), NDUFB8 (ab110242,
Abcam), SDHA (ab14715,Abcam),UQCRC2 (ab14745,Abcam),MT-
COI (ab14705, Abcam), ATP5B (ab14730, Abcam), β-actin (A5316,
Sigma) and VDAC (ab14734, Abcam). Following incubation
with horseradish peroxidase-conjugated secondary antibodies
(Dako) for 1 h at room temperature, detected proteins were
visualized with Clarity Western ECL substrate (Bio-Rad) using
the Bio-Rad ChemiDoc MP with Image Lab software according to
manufacturer’s guidelines.
Northern blotting
Total RNA was extracted from cultured fibroblasts and cardiac
muscle using Trizol reagent (ThermoFisher Scientific) according
to the manufacturer’s instructions. To preserve the aminoacy-
lation state the final RNA pellet was re-suspended in 10 mm
NaOAc at pH 5.0. To investigate the aminoacylation status of
mt-tRNAs, RNA (4 μg) was separated on long (16 cm length)
6.5% polyacrylamide gel (19:1 acrylamide:bis-acrylamide)
containing 8 M urea in 0.1 M NaOAc, pH 5.0. The control
of fully deacylated tRNA (dAc) was obtained by incubation
of control RNA at 75◦C (pH 9.0) for 15 min. To determine
mt-tRNAAla steady-state levels the samples were run on
10 cm gel. Northern hybridization was performed with ϒ-32P
labelled oligonucleotide probes: 5′-GTGGCTGATTTGCGTTCAGT-
3′ for the mt-tRNAAla, 5′-GAGTCGAAATCATTCGTTTTG-3′ for
the mt-tRNAArg and 5′-GTTGTTAGACATGGGGGCAT-3′ for mt-
tRNASer(AGY). Radioactive signal was detected by PhosphorImager
plate using Typhoon scanner and quantified with the Image-
Quant v5.0 software (GE Healthcare).
Cloning, gene expression and protein purification of
human mt-AlaRS
Gene expression and protein purification of human mt-AlaRS
and the p.Arg580Trpmutant were performed as earlier described
(33). The host strain used was Escherichia coli Rosetta (DE3).
Transcription of human mt-tRNAAla
Transcription of human mt-tRNAAla and 32P-labelling of human
mt-tRNAAla were performed as earlier described (33).
ATP-PPi exchange assay
ATP-PPi exchange assay of humanmt-AlaRS and the p.Arg580Trp
mutant was performed as earlier described (33). The reaction
buffer contained 50 mm Tris-HCl (pH 8.0), 20 mm KCl, 10 mm
MgCl2, 2 mm DTT, 4 mm ATP, 5 mm Ala, 2 mm tetrasodium
[32P]pyrophosphate and 200 nM enzyme at 37◦C.
Aminoacylation activity
Aminoacylation assay of humanmt-tRNAAla and the p.Arg580Trp
mutant was performed as earlier described (33). The reaction
buffer contained 50 mm Tris-HCl (pH 8.0), 20 mm KCl, 10 mm
MgCl2, 2 mm DTT, 4 mm ATP, 1 M Ser, 4 μM human mt-tRNAAla,
0.455 μM [32P]tRNAAla (54 000 cpm) and 2 μM human mt-AlaRS
and the p.Arg580Trp mutant at 37◦C.
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Misaminoacylation assay
Misaminoacylation assay was performed in a reaction buffer
containing 50 mm Tris-HCl (pH 8.0), 20 mm KCl, 10 mm MgCl2,
2 mm DTT, 4 mm ATP, 1 M Ser, 4 μM humanmt-tRNAAla, 0.455 μM
[32P]tRNAAla (54 000 cpm) and 2 μM human mt-AlaRS and the
p.Arg580Trp mutant at 37◦C. Assay processing was performed
as previously described (45). The amount of Ser-[32P]AMP
produced was calculated by multiplying the total amount of
tRNAAla (including [32P]tRNAAla and unlabelled tRNAAla) by the
relative level of charged tRNAAla in the aliquots: [Ser-[32P]AMP/
(Ser-[32P]AMP + [32P]AMP)].
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